Psychedelics Market Trends: H1 2026 Review and Forecast

Psychedelics market performance and investor sentiment

The psychedelic medicine sector has been on a rally after a sharp uptick following Trump's executive order, posting compelling year-to-date gains that signal a broader resurgence in investor confidence.

Leading the charge, the Psychedelic Invest Index, a proprietary, market-cap-weighted index designed to track the total market performance of publicly traded companies in the psychedelics sector, is up by over 35 percent.

Clinical-stage heavyweights have also seen massive gains, particularly Definium Therapeutics (NASDAQ:DFTX), a company with positive Phase 3 trial results for its LSD-based candidate (DT120) in major depressive disorder. Its share price is up a significant 236.67 percent year-to-date.

Compass Pathways (NASDAQ:CMPS) and AtaiBeckley (NASDAQ:ATAI), up 76.52 and 74.45 percent this year, respectively, are also advancing trials for treatment-resistant depression.

For retail and institutional investors using broader basket exposure, the AdvisorShares Psychedelics ETF (ARCA:PSIL) has delivered a return of nearly 40 percent so far in 2026.

“Psychedelics … are up very nicely year-to-date and over the past year,” said Dan Ahrens, managing director, COO and CIO at AdvisorShares, and also the primary portfolio manager for PSIL.

“There’s a lot more societal acceptance … and rulings from the FDA in acceptance of alternative treatments that are needed for PTSD, traumatic brain injury, untreatable depression and all sorts of uses.”

Compared to the cannabis sector, which has also seen an uptick based on policy reform in the US, the underlying mechanisms for creating value in psychedelics differ fundamentally.

“These are real biotech companies. They have things in FDA trials. They trade based on their intellectual property and where things stand in FDA trials. And a lot of things are getting fast tracked in that space," he said.

While the industry expert views Trump's executive order as a pivotal shift, he was quick to point out that the psychedelics industry is still nascent and made largely of pre-profit, micro-cap investments highly dependent on clinical trial results; they might get fast tracked for failure just as much as fast tracked for approval.

“Anytime you’re investing in micro-cap stocks, primarily biotech-related and psychedelic-related, it should only be a small part of someone’s portfolio, and they should understand the risks,” Ahrens cautioned earlier this year.

Regulatory progress and market validation

Analysts at ARK Invest view Johnson & Johnson's (NYSE:JNJ) Spravato, a ketamine-derived nasal spray approved by the FDA for treatment-resistant depression in 2019, as a commercial template for the sector, citing its successful market adoption as proof-of-concept for commercial-stage psychedelics.

As the next generation of therapies advances toward commercial availability, regulatory bodies are smoothing the path. Compass Pathways and Transcend Therapeutics have both received Commissioner’s National Priority Vouchers, with Compass also granted an FDA rolling review for its psilocybin treatment, COMP360.

Reporting from Compass as of early July indicates that its rolling new drug application submission is underway, with the final submission expected in the fourth quarter of 2026.

Additionally, the non-profit medical research organization Usona Institute was awarded a voucher to support its uAspire Phase 3 trial evaluating psilocybin for major depressive disorder. AtaiBeckley is similarly well positioned to benefit from this accelerated environment with its 5-MeO-DMT formulation, BPL-003.

Regulatory tailwinds and late-stage trial readouts triggered dramatic market reactions during H1. Shares of Definium Therapeutics soared to US$36.67 — a 144 percent spike from its January opening price — after its antidepressant psychedelics candidate delivered what Needham analyst Ami Fadia called “unprecedented” clinical effects.

Beyond public market swings, Eli Lilly's (NYSE:LLY) announcement of a definitive agreement to acquire psychedelic drugmaker AtaiBeckley further validates Big Pharma’s appetite for the sector. AtaiBeckley is set up to benefit from the accelerated environment with its 5-MeO-DMT formulation, BPL-003.

The deal, worth an estimated US$3.8 billion, is expected to close in the third quarter of 2026 and marks one of the largest acquisitions in psychedelic biotech history.

Investor takeaway

While the tide is undeniably rising, investors must balance long-term optimism with calculated risk management.

To navigate H2 and beyond, success will depend on identifying companies with robust intellectual property portfolios, clear regulatory fast tracks and sufficient capital runways to weather the final stretch to commercial execution.